PL3681500T3 - Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności - Google Patents
Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzrocznościInfo
- Publication number
- PL3681500T3 PL3681500T3 PL19729883.9T PL19729883T PL3681500T3 PL 3681500 T3 PL3681500 T3 PL 3681500T3 PL 19729883 T PL19729883 T PL 19729883T PL 3681500 T3 PL3681500 T3 PL 3681500T3
- Authority
- PL
- Poland
- Prior art keywords
- presbyopia
- treatment
- pilocarpine hydrochloride
- pilocarpine
- hydrochloride
- Prior art date
Links
- 229960002139 pilocarpine hydrochloride Drugs 0.000 title 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 title 1
- 201000010041 presbyopia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662144P | 2018-04-24 | 2018-04-24 | |
| US201862780117P | 2018-12-14 | 2018-12-14 | |
| US201962790957P | 2019-01-10 | 2019-01-10 | |
| PCT/US2019/028917 WO2019209955A2 (en) | 2018-04-24 | 2019-04-24 | Presbyopia treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3681500T3 true PL3681500T3 (pl) | 2022-08-01 |
Family
ID=66821312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19729883.9T PL3681500T3 (pl) | 2018-04-24 | 2019-04-24 | Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności |
Country Status (25)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7274475B2 (ja) | 2017-07-20 | 2023-05-16 | セインダ ファーマシューティカル グアンジョウ コーポレイション | 近視の処置のための組成物および方法 |
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| US12161629B2 (en) | 2018-10-15 | 2024-12-10 | Opus Genetics, Inc. | Methods and compositions for treatment of glaucoma and related conditions |
| CN113164452A (zh) | 2018-10-26 | 2021-07-23 | 奥库菲尔制药股份有限公司 | 治疗老花眼、散瞳和其他眼部疾病的方法和组合物 |
| EP4210690B1 (en) * | 2020-09-11 | 2025-01-29 | Intratus-Nevada, Inc. | Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity |
| CA3210064A1 (en) * | 2021-01-28 | 2022-08-04 | Glaukos Corporation | Formulations |
| WO2022232205A1 (en) * | 2021-04-28 | 2022-11-03 | Lenz Therapeutics, Inc. | A method of reducing brow ache |
| CN115368310B (zh) | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
| US12180206B2 (en) | 2021-11-17 | 2024-12-31 | Lenz Therapeutics Operations, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| WO2023125544A1 (zh) | 2021-12-28 | 2023-07-06 | 沈阳兴齐眼药股份有限公司 | 组合物及其在制备用于治疗老花眼的药物中的用途 |
| US11857538B2 (en) | 2022-01-14 | 2024-01-02 | Somerset Therapeutics, Llc | Stable pilocarpine formulations with modified buffer characteristics and related methods |
| US11969410B2 (en) | 2022-02-09 | 2024-04-30 | Somerset Therapeutics, Llc | Low pH pilocarpine and brimonidine compound formulations and related methods |
| CN119584954A (zh) | 2022-04-21 | 2025-03-07 | 格劳科斯公司 | 眼用局部乳膏组合物 |
| US20230372303A1 (en) | 2022-05-18 | 2023-11-23 | Glaukos Corporation | Applications of zwitterions in ophthalmic topical cream compositions and preparations |
| CN117243888A (zh) * | 2023-09-22 | 2023-12-19 | 南京海纳制药有限公司 | 一种含有盐酸毛果芸香碱滴眼水性药物组合物及其制备方法 |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| US5122522A (en) | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
| US5055467A (en) | 1989-11-13 | 1991-10-08 | Allergan, Inc. | Pharmaceutical epinephrine-pilocarpine compounds |
| US5496471A (en) | 1990-01-08 | 1996-03-05 | Ciba-Geigy Corporation | Apparatus for removing components from solutions |
| US5776916A (en) | 1990-07-10 | 1998-07-07 | Gramer; Eugen | Medicament for reducing the intraocular pressure |
| CA2064160C (en) | 1991-03-27 | 1998-08-11 | Paul J. T. Missel | Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| JPH07508751A (ja) | 1992-07-02 | 1995-09-28 | テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド | 老視治療のための方法および生産品 |
| SE512871C2 (sv) | 1992-08-20 | 2000-05-29 | Santen Oy | Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension |
| AU5599594A (en) * | 1992-11-16 | 1994-06-08 | Ciba-Geigy Ag | Polyvinyl alcohol/borate ophthalmic drug delivery system |
| US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| SE9401109D0 (sv) * | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
| US5574518A (en) | 1995-01-10 | 1996-11-12 | Les Laboratoires Opti-Centre Inc. | System incorporation two different sphero-non-spherical contact lenses for correcting presbytia |
| US5612027A (en) | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| US6164282A (en) | 1999-01-27 | 2000-12-26 | Allergan Sales, Inc. | Methods for restoring and/or enhancing accommodation in pseudo phakia |
| CH693625A5 (it) | 1999-02-18 | 2003-11-28 | Inpharma Sa | Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi. |
| IT1306135B1 (it) | 1999-04-26 | 2001-05-30 | Farmigea Spa | Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto. |
| AU7581000A (en) | 1999-09-16 | 2001-04-17 | Gerald D. Horn | A method for optimizing pupil size using alpha antagonist |
| US6420407B1 (en) | 1999-09-16 | 2002-07-16 | Gerald Horn | Ophthalmic formulation which modulates dilation |
| TWI227143B (en) | 1999-12-15 | 2005-02-01 | Guo-Jiun Sung | In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method |
| US6218428B1 (en) | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| WO2002024116A1 (en) | 2000-09-20 | 2002-03-28 | Shahinian, Lee, Jr. | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
| US6273092B1 (en) | 2000-09-22 | 2001-08-14 | Gerard M. Nolan | Methods for treating various eye disorders |
| ITMI20010708A1 (it) | 2001-04-03 | 2002-10-03 | Alessandro Randazzo | Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter |
| US20030139737A1 (en) | 2002-01-24 | 2003-07-24 | J.T. Lin | Method and apparatus for treatment of presbyopia by lens relaxation and anterior shift |
| CA2493581C (en) | 2002-07-30 | 2014-12-23 | Omeros Corporation | Ophthalmologic irrigation solutions and method |
| US20070211212A1 (en) | 2002-09-26 | 2007-09-13 | Percy Bennwik | Eye state sensor |
| US20050261641A1 (en) | 2002-09-26 | 2005-11-24 | Warchol Mark P | Method for ophthalmic administration of medicament |
| US20040078009A1 (en) | 2002-10-17 | 2004-04-22 | Lin J. T. | Method and apparatus for the treatment of presbyopia and other eye disorders combining pharmocological and surgical means |
| US20050205101A1 (en) * | 2002-10-17 | 2005-09-22 | Lin J T | Combined pharmocological and surgical method and system for the treatment of eye disorders |
| US20060177430A1 (en) | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
| EP1592435A4 (en) | 2002-12-20 | 2008-01-23 | Chakshu Res Inc | EYE FORMULATION FOR THE PREVENTION AND TREATMENT OF EYE DRESS |
| EP2163643B1 (en) | 2003-03-05 | 2015-01-21 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20050119262A1 (en) | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
| PL1754491T3 (pl) | 2004-05-21 | 2010-08-31 | Senju Pharma Co | Preparat do oczu do wchłaniania przezskórnego zawierający agonistę receptora muskarynowego |
| US20050279369A1 (en) | 2004-06-21 | 2005-12-22 | Lin J T | Method and apparatus for the treatment of presbyopia and glaucoma by ciliary body ablation |
| CA2614519A1 (en) | 2004-10-22 | 2006-05-04 | Omer Yilmaz | System and method for aligning an optic with an axis of an eye |
| BRPI0615432A2 (pt) | 2005-09-02 | 2011-05-17 | Theravida Inc | composição farmacêutica, e, uso de compostos |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| DK2038252T3 (en) | 2006-07-12 | 2016-12-19 | Univ Tennessee Res Found | SUBSTITUTED AND ACYLANILIDER methods of use thereof |
| ATE439863T1 (de) | 2006-12-18 | 2009-09-15 | Jorge Luis Benozzi | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie |
| WO2009046967A1 (en) | 2007-10-08 | 2009-04-16 | Fovea Pharmaceuticals Sa | Aqueous ophthalmic formulations |
| AU2015202175A1 (en) | 2007-12-15 | 2015-05-14 | Anant Sharma | Optical correction |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| WO2010125416A1 (en) | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
| WO2010135731A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| TW201109325A (en) | 2009-07-30 | 2011-03-16 | Wakamoto Pharma Co Ltd | Aqueous composition for eye drops |
| AR081049A1 (es) | 2010-08-17 | 2012-06-06 | Gonzalez Santos Alejandro Raul | Medicamento oftalmico para el tratamiento de la hipermetropia |
| US9119772B2 (en) * | 2011-01-26 | 2015-09-01 | Allergan, Inc. | Androgen composition for treating an opthalmic condition |
| UA113525C2 (xx) | 2011-09-20 | 2017-02-10 | Спосіб лікування пресбіопії | |
| AU2012322917B2 (en) | 2011-10-12 | 2016-11-03 | Ascendis Pharma Ophthalmology Division A/S | Prevention and treatment of ocular conditions |
| US20130157963A1 (en) | 2011-12-16 | 2013-06-20 | Allergan, Inc. | Ophthalmic compositions comprising polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers |
| EP2630952A1 (en) | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
| US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| EP2950800B1 (en) | 2013-02-01 | 2020-09-09 | Ocuphire Pharma, Inc. | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
| US9795560B2 (en) | 2013-02-01 | 2017-10-24 | Ocularis Pharma, Llc | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
| US8859623B1 (en) | 2013-11-14 | 2014-10-14 | Paragon BioTeck, Inc. | Methods and compositions of stable phenylephrine formulations |
| ES2538551B1 (es) | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
| EP3750541A1 (en) | 2014-01-10 | 2020-12-16 | Santen Pharmaceutical Co., Ltd | Pharmaceutical preparation containing pyridylaminoacetic acid compound |
| AU2014382677A1 (en) | 2014-02-11 | 2016-09-01 | Orasis Pharmaceuticals Ltd. | Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| US20190000808A1 (en) | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
| CH711969A2 (it) | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
| US10231968B2 (en) | 2016-08-01 | 2019-03-19 | David R. Hardten | Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies |
| WO2018033792A2 (en) | 2016-08-19 | 2018-02-22 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
| EP3525885B1 (en) | 2016-10-12 | 2022-01-26 | PS Therapy Ltd. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
-
2019
- 2019-04-24 PL PL19729883.9T patent/PL3681500T3/pl unknown
- 2019-04-24 CN CN201980037652.3A patent/CN112272558A/zh active Pending
- 2019-04-24 RS RS20220575A patent/RS63360B1/sr unknown
- 2019-04-24 EP EP19729883.9A patent/EP3681500B2/en active Active
- 2019-04-24 HU HUE19729883A patent/HUE058931T2/hu unknown
- 2019-04-24 EP EP22160205.5A patent/EP4066830A1/en active Pending
- 2019-04-24 SG SG11202010472XA patent/SG11202010472XA/en unknown
- 2019-04-24 US US16/393,175 patent/US10610518B2/en active Active
- 2019-04-24 ES ES19729883T patent/ES2920803T5/es active Active
- 2019-04-24 SI SI201930260T patent/SI3681500T1/sl unknown
- 2019-04-24 WO PCT/US2019/028917 patent/WO2019209955A2/en not_active Ceased
- 2019-04-24 KR KR1020237017632A patent/KR20230079489A/ko active Pending
- 2019-04-24 JP JP2020559558A patent/JP6946575B2/ja active Active
- 2019-04-24 CA CA3074618A patent/CA3074618C/en active Active
- 2019-04-24 DK DK19729883.9T patent/DK3681500T3/da active
- 2019-04-24 MX MX2020011301A patent/MX2020011301A/es unknown
- 2019-04-24 LT LTEPPCT/US2019/028917T patent/LT3681500T/lt unknown
- 2019-04-24 CA CA3162141A patent/CA3162141A1/en active Pending
- 2019-04-24 HR HRP20220762TT patent/HRP20220762T1/hr unknown
- 2019-04-24 KR KR1020207033656A patent/KR20210005134A/ko not_active Ceased
- 2019-04-24 PT PT197298839T patent/PT3681500T/pt unknown
- 2019-04-24 AU AU2019261598A patent/AU2019261598B9/en not_active Ceased
- 2019-04-24 BR BR112020021845-6A patent/BR112020021845A2/pt not_active IP Right Cessation
-
2020
- 2020-02-14 US US16/791,039 patent/US11285134B2/en active Active
- 2020-05-21 AU AU2020203311A patent/AU2020203311A1/en not_active Abandoned
- 2020-10-20 IL IL278178A patent/IL278178A/en unknown
- 2020-10-22 CL CL2020002734A patent/CL2020002734A1/es unknown
- 2020-10-23 PH PH12020551766A patent/PH12020551766A1/en unknown
- 2020-11-24 CO CONC2020/0014563A patent/CO2020014563A2/es unknown
-
2021
- 2021-09-15 JP JP2021150116A patent/JP7470667B2/ja active Active
-
2022
- 2022-01-12 US US17/647,813 patent/US20220241245A1/en not_active Abandoned
- 2022-02-18 AU AU2022201106A patent/AU2022201106A1/en not_active Abandoned
- 2022-06-22 CY CY20221100430T patent/CY1125325T1/el unknown
-
2024
- 2024-03-29 US US18/621,624 patent/US20240382462A1/en not_active Abandoned
- 2024-04-08 JP JP2024062082A patent/JP2024096131A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3681500T1 (sl) | Uporaba pilokarpinijevega hidroklorida za zdravljenje presbiopije | |
| IL276398B1 (en) | Combination therapy for mastocytosis | |
| GB201820166D0 (en) | Therapeutic agents | |
| GB201820165D0 (en) | Therapeutic agents | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
| IL287280A (en) | Compounds and methods for the treatment of ocular disorders | |
| IL283948A (en) | Methods for treating depression | |
| GB201902277D0 (en) | Therapeutic agents | |
| IL290756A (en) | Treatment of azoles | |
| IL287264A (en) | Compounds and methods for the treatment of ocular disorders | |
| GB201805816D0 (en) | Therapeutic agents | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL283031A (en) | And will grow to treat the symptoms of overactivity in the gland | |
| IL281997A (en) | Combined treatment for the treatment of uveal melanoma | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| GB201914296D0 (en) | Treatment | |
| GB201912365D0 (en) | Treatment | |
| GB201912760D0 (en) | Treatment | |
| GB201912335D0 (en) | Treatment | |
| GB201901130D0 (en) | Formulation for the treatment of tendinopathies | |
| GB201911603D0 (en) | Treatment | |
| GB201910755D0 (en) | Treatment | |
| HK40032581A (en) | Combination therapy for the treatment of mastocytosis | |
| GB201904253D0 (en) | Treatment |